p38

(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro).

AR420626 is an oral active and selective agonist of free fatty acid receptor 3 (FFAR3) with an EC 50 value of 2.2µM.

p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM).

An active metabolite of disulfiram

Selective p38α/β inhibitor; orally bioavailable

N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK.

(+)-Isomenthone is an isomer of L-Menthone, isolated from Ziziphora clinopodioidesLam. and possesses antioxidant activity.

XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.

MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.

p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6.

(Rac)-Hesperetin is the racemate of Hesperetin.

Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum.

5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect.

(E)-Osmundacetone is the isomer of Osmundacetone.

TRi-1 is a potent, specific, and irreversible inhibitor of TXNRD1 and TXNRD2 with IC 50 values of 18nM and 44nM.

MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.

EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.

Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits anti-inflammatory and anti-infectious properties.

Anti-inflammatory agent 35 (compound 5a27) is an orally effective curcumin analogue with anti-inflammatory activity. It can block the signaling of mitogen-activated protein kinase (MAPK) and nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits neutrophil infiltration and proinflammatory cytokine production in vitro. In vivo studies have shown that Anti-inflammatory agent 35 significantly alleviates acute lung injury (ALI) induced by lipopolysaccharide (LPS).

BSJ-04-122 is a covalent dual inhibitor of MKK4/7. It inhibits both MKK4 and MKK7 with IC50 values of 4 nM and 181 nM, respectively. BSJ-04-122 can be used in cancer research.

Cyclocurcumin is an effective inhibitor of p38α. It has anti-rheumatic, anti-vasoconstrictive and antioxidant activities.

Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K).

OVA-E1 peptide TFA is an antagonist mutant of SIINFEKL [OVA (257-264)]. OVA-E1 peptide activates the p38 and JNK cascades in both mutant and wild-type thymocytes.

Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM).